Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels.
Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels.
复制标题
DOI：
10.1007/s11126-017-9515-x
复制
发表时间：
2018-03
期刊：
影响因子：
--
通讯作者：
Kelly DL
中科院分区：
文献类型：
--
作者：
Wehring HJ;Elsobky T;McEvoy JP;Vyas G;Richardson CM;McMahon RP;DiPaula BA;Liu F;Sullivan K;Buchanan RW;Feldman S;McMahon EM;Kelly DL
Clozapine is the sole antipsychotic agent effective for the treatment of refractory schizophrenia. Sixty percent of clozapine-treated patients, however, fail to adequately respond. Minocycline, a tetracycline antibiotic, possesses antiinflammatory and neuroprotective properties that may play a role in schizophrenia. Clozapine is mainly metabolized by CYP1A2 enzymes, and minocycline may potentially inhibit CYP1A2 as hypothesized by case report data. To date, no pharmacokinetic interaction has been reported between minocycline and clozapine. This is a secondary analysis of a 10-week controlled study of adjunctive minocycline to clozapine in treatment refractory schizophrenia. Clozapine plasma levels were collected every two weeks during the study. 28 participants assigned to receive minocycline and 22 assigned to placebo were included. No differences existed in baseline demographics, clozapine dose or plasma levels. Average changes from baseline in clozapine plasma level (p= 0.033) were significantly higher in the minocycline group despite maintenance of stable doses. No statistically significant treatment differences were found in the norclozapine (p= 0.754) or total clozapine (p= 0.053) changes in plasma levels, although possible changes in total clozapine levels require further investigation. This analysis suggests that minocycline administration may lead to increased clozapine plasma levels. Further study is needed to examine possible explanations.
登录
查看更多内容
DOI：
10.2174/1872213x08666141029123524
发表时间：
2014-01-01
影响因子：
4.2
作者：
Ghanizadeh, Ahmad;Dehbozorgi, Sara;Rezaei, Zahra
通讯作者：
Rezaei, Zahra
影响因子：
3.6
作者：
Fang, J;Coutts, RT;Baker, GB
通讯作者：
Baker, GB
影响因子：
2.9
作者：
Kelly DL;Sullivan KM;McEvoy JP;McMahon RP;Wehring HJ;Gold JM;Liu F;Warfel D;Vyas G;Richardson CM;Fischer BA;Keller WR;Koola MM;Feldman SM;Russ JC;Keefe RS;Osing J;Hubzin L;August S;Walker TM;Buchanan RW
通讯作者：
Buchanan RW
DOI：
10.1590/s0100-879x2009001100002
发表时间：
2009-11-01
影响因子：
2.3
作者：
Chaves, C.;Marque, C.R.;Hallak, J.E.
通讯作者：
Hallak, J.E.
影响因子：
4.1
作者：
Qurashi, I.;Collins, J. D.;Husain, N.
通讯作者：
Husain, N.